HEM Pharma Inc

HEM Pharma Inc exhibits a highly leveraged capital structure, with a debt-to-equity ratio of 3.86, indicating significant reliance on debt financing. The company's liquidity position is weak, as evidenced by a current ratio of 0.56, and its free cash flow of -31,113,441,970 KRW reflects ongoing cash outflows. Despite a high price-to-book ratio of 88.16, the company's negative net income of -23,842,029,330 KRW and negative return on equity of -4.78% suggest poor capital efficiency. The company's profitability metrics are well below industry norms, with a negative return on assets of -0.46 and an operating margin of -119.9%, indicating substantial operational inefficiencies. The company's gross profit margin of 4.86% is also weak, suggesting high production or service delivery costs relative to revenue. These metrics highlight a need for operational restructuring to align with industry benchmarks. HEM Pharma Inc's revenue is concentrated in its two core businesses: customized healthcare services and LBP discovery platform services. The company does not disclose geographic revenue breakdowns, but its operations are primarily based in South Korea. This lack of geographic diversification may expose the company to regional economic or regulatory risks. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. Historical revenue of 12,979,352,490 KRW is offset by a net loss of -23,842,029,330 KRW, indicating a lack of profitability despite revenue generation. The absence of clear growth drivers or market expansion plans raises concerns about long-term sustainability. The company faces medium liquidity risk due to negative free cash flow and a current ratio below 1, and its debt load is a key risk factor. The risk assessment indicates a low dilution risk, but the company's negative net cash position after subtracting total debt suggests potential refinancing challenges. No recent filings or transcripts were provided to assess management's response to these risks. No recent events or filings were disclosed in the input data to provide insight into the company's strategic direction or operational developments.